Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: xeneticbio.com
SC 13D/A - Xenetic Biosciences, Inc. (0001534525) (Subject)
SC 13D/A - Xenetic Biosciences, Inc. (0001534525) (Subject)
SC 13D - Xenetic Biosciences, Inc. (0001534525) (Subject)
SC 13G - Xenetic Biosciences, Inc. (0001534525) (Subject)
Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical development opportunityDNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indicationsXenetic plans to conduct a Phase 1 clinical study of lead asset in locally advanced or metastatic solid tumorsCompany to host update conference call and webcast today, April 27th at 8:30 AM ETFRAMINGHAM, MA / ACCESSWIRE / April 27, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatm
8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
10-Q - Xenetic Biosciences, Inc. (0001534525) (Filer)
25-NSE - Xenetic Biosciences, Inc. (0001534525) (Subject)
8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
10-Q - Xenetic Biosciences, Inc. (0001534525) (Filer)
10-K/A - Xenetic Biosciences, Inc. (0001534525) (Filer)
8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
10-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.79) by 1.27 percent. The company reported quarterly sales of $510.817 thousand which missed the analyst consensus estimate of $650.000 thousand by 21.41 percent. This is a 15.69 percent decrease over sales of $605.844 thousand the same period last year.
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.87) by 11.49 percent. This is a 23 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $671.96 thousand which missed the analyst consensus estimate of $680.00 thousand by 1.18 percent. This is a 37.99 percent increase over sales of $486.97 thousand the same period last year.
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly earnings of $0.77 per share which beat the analyst consensus estimate of $(0.87) by 188.51 percent. This is a 177 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $671.96 thousand which missed the analyst consensus estimate of $680.00 thousand by 1.18 percent. This is a 37.99 percent increase over sales of $486.97 thousand the same period last year.
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform
Gainers PHAXIAM Therapeutics (NASDAQ:PHXM) shares moved upwards by 22.1% to $5.13 during Tuesday's regular session. The market value of their outstanding shares is at $31.1 million. Travere Therapeutics (NASDAQ:TVTX) stock moved upwards by 20.66% to $7.59. The market value of their outstanding shares is at $570.3 million. MSP Recovery (NASDAQ:LIFW) stock rose 18.99% to $4.0. The market value of their outstanding shares is at $57.2 million. Xenetic Biosciences (NASDAQ:XBIO) stock rose 17.84% to $4.16. The company's market cap stands at $6.4 million. Cerevel Therapeutics Hldg (NASDAQ:CERE) shares moved upwards by 16.28% to $36.98. The company's market cap stands at $6.6 billion. Kala Bio
Xenetic Biosciences (NASDAQ:XBIO) reported its Q3 earnings results on Friday, November 10, 2023 at 08:35 AM. Here's what investors need to know about the announcement. Earnings Xenetic Biosciences beat estimated earnings by 38.39%, reporting an EPS of $-0.69 versus an estimate of $-1.12. Revenue was up $196 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.44 which was followed by a 0.83% increase in the share price the next day. To track all earnings releases for Xenetic Biosciences visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(1.12) by 38.39 percent. This is a 15 percent decrease over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $611.17 thousand which beat the analyst consensus estimate of $460.00 thousand by 32.86 percent. This is a 47.54 percent increase over sales of $414.25 thousand the same period last year.
Gainers Evelo Biosciences (NASDAQ:EVLO) stock increased by 60.7% to $0.19 during Tuesday's pre-market session. The company's market cap stands at $21.6 million. DICE Therapeutics (NASDAQ:DICE) shares moved upwards by 38.07% to $46.74. The market value of their outstanding shares is at $2.2 billion. Nuwellis (NASDAQ:NUWE) stock moved upwards by 34.81% to $3.95. The company's market cap stands at $4.7 million. Biofrontera (NASDAQ:BFRI) shares increased by 29.54% to $0.57. The company's market cap stands at $15.2 million. Innovative Eyewear (NASDAQ:LUCY) shares increased by 25.11% to $2.74. The market value of their outstanding shares is at $23.0 million. Cano Health (NYSE:CANO) stock inc
HC Wainwright has downgraded Xenetic Biosciences Inc (NASDAQ:XBIO) from Buy to Neutral, citing pending clinical path visibility. In the Q1 earnings release, the company announced continued progress with the DNase-based oncology program toward Phase 1 study for pancreatic carcinoma and other locally advanced or metastatic solid tumors. Xenetic announced a one-for-ten reverse stock split, the second reverse split in four years. The analyst noted that the split is not necessarily concerning amid this volatile healthcare market. But the analyst is moving to the sidelines due to volatile markets combined with a lack of catalysts to shore up the shares. The analyst has downgraded based on th
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
3 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
Ongoing preclinical studies with data expected before year endFocus on demonstration of DNase-based oncology program in clinical proof-of-concept studies in multiple indicationsEnded the quarter with $7.3 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / August 14, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the second quarter of 2024. "We remain confident in the potential of our DNase-based oncology platform and continue to advance our preclinical studies with data expected before
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of James Parslow, the Company's Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024."I am a strong believer in the potential of our innovative immune-oncology technologies addressing hard-to-treat cancers. This management change will allow us to focus our resources on driving our pipeline toward
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsEnded the quarter with $7.8 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / May 10, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the first quarter of 2024 and provided a business update."We have initiated several
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platformFRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia ("UVA") to advance the development of its systemic DNase program. Xenetic's DNase-based oncology platform is designed to target neutrophil extracellular traps ("NETs"), which are weblike structures co
Encouraging growing body of preclinical data guiding pathway to first in human trial for DNase-based oncology platformDriving development towards Phase 1 program for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsContinuing partnering discussions to advance development of systemic DNase and DNase-Armored CAR T programsEnded the quarter with $9.8 million of cash to fund operationsFRAMINGHAM, MA / ACCESSWIRE / November 10, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial re
- Live video webcast interactive Q&A with participating companies -FRENCHTOWN, NJ / ACCESSWIRE / October 18, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor "Ask the CEO" Conference, October 24-25, 2023. The "Ask the CEO" conference is intended to provide the investment community with access to ask their questions directly to management of participating companies. Investors and interested parties will have the opportunity to submit questions live during the event. Questions can also be pre-submitted leading up to the event through the Q&A Submission links below. Participating companies will an
Live moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ETFRAMINGHAM, MA / ACCESSWIRE / October 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences, will participate at the Virtual Investor Ask the CEO Conference on October 24, 2023 at 1:00 PM ET.The "Ask the CEO" conference is intended to provide the investment community with access to ask their questions directly to man
FRAMINGHAM, MA / ACCESSWIRE / September 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.In addition to the presentation, management will be available to participate in in-person and virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about
- Company continues to execute on plan to advance DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsFRAMINGHAM, MA / ACCESSWIRE / August 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the second quarter of 2023. "Since the beginning of 2023, we have taken important, fundamental steps to further advance our DNase-based oncology platform. We have secured strategic collaborations, bolstered
- Event taking place on July 11th, 12th, and 13th -- Live video webcast with moderated interactive discussion with participating companies -- Access the event at www.virtualinvestorco.com -FRENCHTOWN, NJ / ACCESSWIRE / July 6, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the presenting company line-up for its Virtual Investor Summer Spotlight Series being held on July 11-13, 2023. The virtual event will include a moderated roundtable discussion or company presentation and an interactive Q&A session allowing for questions from the conference attendees.The schedule for the event is as follows:Tuesday, July 11, 202311:00 AM ET
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of James Parslow, the Company's Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024."I am a strong believer in the potential of our innovative immune-oncology technologies addressing hard-to-treat cancers. This management change will allow us to focus our resources on driving our pipeline toward
Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertiseFRAMINGHAM, MA / ACCESSWIRE / May 4, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Reid P. Bissonnette, Ph.D. to serve as an executive consultant for translational research and development and to support the advancement of the Company's DNase-based oncology platform. Xenetic's DNase-based oncology platform is designed to target neutrophil extrace
Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planningFRAMINGHAM, MA / ACCESSWIRE / May 3, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Scott N. Cullison to serve as an executive consultant for business development and to support the advancement of the Company's DNase-based oncology platform. Mr. Cullison brings over 20 years of experience in the pharmaceutical industry. He has amassed a broad range
Appointment of Dr. Spicer to Scientific Advisory Board bolsters expertise in Neutrophil Extracellular Traps ("NETs") in cancer biology and provides valuable assistance in advancing development of the Company's DNase platformFRAMINGHAM, MA / ACCESSWIRE / November 16, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of Jonathan Spicer, MD, PhD to its Scientific Advisory Board ("SAB").Dr. Spicer is recognized as a leader in understanding how neutrophils impact cancer progression, in particular, the rol
FRAMINGHAM, MA / ACCESSWIRE / October 4, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the appointment of Allan Tsung, MD to its Scientific Advisory Board.Dr. Tsung is a nationally and internationally recognized leader specializing in evaluating and caring for patients with liver, bile duct and pancreas cancers and is an expert in laparoscopic and robotic surgery. He currently serves as Chair of the Department of Surgery at the University of Virginia ("UVA") School of Medicine and Director of the Cancer Therapeutics program